ArticleKidney international reports2024
"Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.
Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Kidney transplant outcomes in patients with complement dysregulation.World journal of transplantation · 2026Article
- Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies.Clinical kidney journal · 2026Review
- Complete Blood Count in Delayed Graft Function: A Narrative Review.Annals of transplantation · 2026Review
- Cytomegalovirus viremia associated with systemic thrombotic microangiopathy after kidney transplantation: a case report.Frontiers in medicine · 2026Article
- Complement activation in secondary thrombotic microangiopathies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes.Kidney international reports · 2025Article
- It's Friday, 3 p.m., and the phone rings ... a practical approach to common nephrology consultations-Part 1.Clinical kidney journal · 2025Review
- When should the nephrologist think about genetics in patients with glomerular diseases?Clinical kidney journal · 2025Review
- Efficacy and safety of switching from Eculizumab to Ravulizumab for the maintenance of aHUS remission after kidney transplant: a preliminary experience.Journal of nephrology · 2024Article
- Exuberant Endothelial C5b-9 Formation in Recurrent andKidney international reports · 2024Article
- Response to Letter to the Editor From Bouwmeester RN et al.: "Eculizumab in Postransplant TMA: Unproven Benefit."Kidney international reports · 2024Article
- Letter to the editor about: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.Kidney international reports · 2024Article
- Response to Letter to the Editor From Ville S. et al. About: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.Kidney international reports · 2024Article
- Eculizumab in Posttransplant TMA: Unproven Benefit: A Response to Maritati et al.: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.Kidney international reports · 2024Article
- Response to "A Caution Against the Use of C5B-9 Endothelial Assay to Support Eculizumab Therapy".Kidney international reports · 2024Article
- A Caution Against the Use of C5b-9 Endothelial Assay to Support Eculizumab Therapy: A response to MaritatiKidney international reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Posttransplant thrombotic microangiopathy (PT-TMA) is an uncommon event that characterizes approximately 3% to 14% of kidney transplants (KTs), and that is associated with a higher risk of delayed graft function and graft loss. PT-TMA occurs more frequently within the first 3 months after transplant and can be a manifestation of Methods: We retrospectively analyzed clinical records of 45 KT patients who received eculizumab immediately after the clinical diagnosis of PT-TMA. Results: Kidney biopsy was performed in 91.1% of patients, and complement genetic study was performed in 64.4%. Of the kidney biopsies, 85.4% showed signs of TMA; genetic analysis revealed 1 pathogenetic variant, 2 variants of uncertain significance, 1 likely benign variant, 8 risk polymorphisms, and 27 risk haplotypes. After 2 weeks from the treatment starting, hemoglobin and platelets significantly increased. A remarkable improvement in kidney function was also observed. After 6 months, 28.8% of patients had a complete renal recovery whereas 44.4% had a partial recovery. Conclusion: This is, to our knowledge, the largest series of KT patients with PT-TMA treated with eculizumab. These data suggest that eculizumab is associated with a normalization of hemolysis indices and an important and progressive improvement of graft function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.